Zinc and Selenium Supplementation in Atherosclerosis
Information source: Universidade Federal do Rio Grande do Norte
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dietary Selenium Deficiency; Dietary Zinc Deficiency
Intervention: zinc and selenium supplementation (Dietary Supplement); rosuvastatin + placebo (Other)
Phase: N/A
Status: Completed
Sponsored by: Universidade Federal do Rio Grande do Norte Official(s) and/or principal investigator(s): Dulcineia SP Abdalla, PhD, Study Director, Affiliation: University of São Paulo Lucia FC Pedrosa, PhD, Study Director, Affiliation: University of Rio Grande do Norte
Summary
The aim of this randomized double-blind study was to evaluate the effect of oral zinc and
selenium supplementation on oxidative stress and inflammation biomarkers as well as the
status of zinc and selenium in patients with atherosclerosis and angina stable treated with
rosuvastatin. The hypotheses tested in this study were: Treatment with rosuvastatin impairs
zinc and selenium status in patients with atherosclerosis and stable angina? Zinc and
selenium supplementation, concomitantly with rosuvastatin, influences the antioxidant and
anti-inflammatory as well as the status of minerals?
Clinical Details
Official title: Effect of Zinc and Selenium Supplementation in Patients With Atherosclerosis Treated With Statins
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Change from baseline in zinc and selenium status at 4 months
Secondary outcome: Change from baseline in lipid profile at 4 monthsChange from baseline in zinc and selenium status at 4 months Change from baseline in inflammation biomarkers status at 4 months
Detailed description:
The study included 47 men and 29 women, average age around 60 years, with coronary
atherosclerosis diagnosed by angiography. Data from patients were obtained at beginning and
after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and
selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and
selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL
(LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities,
IL-6 and hs-CRP were evaluated in all patients.
Eligibility
Minimum age: 41 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- The study included adult and elderly patients, with coronary atherosclerosis and
stable angina diagnosed by angiography showing ≥ 70% stenosis of the vessel lumen in
at least one segment of a major epicardial artery or ≥ 50% stenosis of the diameter
of the left main coronary artery, stable angina
Exclusion Criteria:
- Cardiac complications or other serious diseases such as:
- thyroid,
- hematologic,
- congenital,
- autoimmune liver disease,
- kidney failure,
- cancer,
- associated infections,
- osteoporosis,
- post-operative,
- use of:
- antacids,
- antibiotics and
- vitamin-mineral supplements,
- alcohol and
- current smoking.
Locations and Contacts
Onofre Lopes University Hospital, Natal, Rio Grande do Norte 59.012.300, Brazil
Additional Information
Starting date: January 2008
Last updated: March 2, 2012
|